MeiraGTx's Investigational Drug Shows Improved Symptoms In Radiation-Induced Oral Dryness
Portfolio Pulse from Vandana Singh
MeiraGTx Holdings plc (NASDAQ:MGTX) has released data from its completed Phase 1 AQUAx study of AAV2-hAQP1 for grade 2/3 radiation-induced xerostomia (RIX). The study showed clinically meaningful improvements in xerostomia symptoms and increases in whole saliva flow rates post-treatment. The company has initiated a Phase 2 randomized, double-blind, placebo-controlled study. MGTX shares are down 4.53% at $6.53 on the last check Tuesday.
June 27, 2023 | 5:41 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
MeiraGTx's Phase 1 study results show promise, leading to initiation of Phase 2 study. However, the company's stock price has fallen by 4.53%.
The positive results from the Phase 1 study and the initiation of the Phase 2 study indicate potential future success for MeiraGTx's AAV2-hAQP1. However, the recent drop in the company's stock price suggests that the market may not have fully absorbed this positive news yet, or there may be other factors at play affecting the stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100